Alto Neuroscience Secures New Patent for ALTO-207 Depression Treatment, Extending Protection Into Mid-2040s
I'm PortAI, I can summarize articles.
Alto Neuroscience Inc. has secured U.S. Patent Number 12,521,374 for its depression treatment ALTO-207, which combines pramipexole and ondansetron. This patent protects the use of ondansetron to reduce side effects from pramipexole, allowing for higher doses to enhance antidepressant effects. The patent is expected to safeguard ALTO-207's intellectual property until the mid-2040s, reinforcing its position in the treatment of resistant depression.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments